APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pegfilgrastim Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pegfilgrastim Injection Market Outlook and Growth Opportunities 2026

23 December 2025196 pages

Choose your research edition.

Industry ResearchPegfilgrastim Injection Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Pegfilgrastim Injection Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Pegfilgrastim Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pegfilgrastim Injection Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Pegfilgrastim Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Pegfilgrastim Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pegfilgrastim Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pegfilgrastim Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pegfilgrastim Injection market include CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi, Amgen Inc. and Coherus BioSciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pegfilgrastim Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pegfilgrastim Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pegfilgrastim Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pegfilgrastim Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Pegfilgrastim Injection Segment by Company

CSPC

Sandoz (Novartis)

Qilu Pharmaceutical

Mylan

Pfizer

Jiangsu Hengrui Medicine

Fresenius Kabi

Amgen Inc.

Coherus BioSciences, Inc.

Biocon Biologics Inc.

Pegfilgrastim Injection Segment by Type

Innovative Drugs

Generic Drugs

Pegfilgrastim Injection Segment by Application

Neoplastic Diseases

Blood Disorders

Others

Pegfilgrastim Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pegfilgrastim Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pegfilgrastim Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pegfilgrastim Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Pegfilgrastim Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pegfilgrastim Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pegfilgrastim Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pegfilgrastim Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pegfilgrastim Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pegfilgrastim Injection industry.

Chapter 3: Detailed analysis of Pegfilgrastim Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pegfilgrastim Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pegfilgrastim Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pegfilgrastim Injection Industry Trends Table 2. Pegfilgrastim Injection Industry Drivers Table 3. Pegfilgrastim Injection Industry Opportunities and Challenges Table 4. Pegfilgrastim Injection Industry Restraints Table 5. Global Pegfilgrastim Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pegfilgrastim Injection Revenue Share by Company (2021-2026) Table 7. Global Pegfilgrastim Injection Sales Volume by Company (units) & (2021-2026) Table 8. Global Pegfilgrastim Injection Sales Volume Share by Company (2021-2026) Table 9. Global Pegfilgrastim Injection Average Price (USD/unit) of Company (2021-2026) Table 10. Global Pegfilgrastim Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pegfilgrastim Injection Key Company Manufacturing Base & Headquarters Table 12. Global Pegfilgrastim Injection Company, Product Type & Application Table 13. Global Pegfilgrastim Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pegfilgrastim Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Innovative Drugs Table 18. Significant Companies of Generic Drugs Table 19. Global Pegfilgrastim Injection Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Pegfilgrastim Injection Sales Volume by Type (2021-2026) & (units) Table 21. Global Pegfilgrastim Injection Sales Volume by Type (2027-2032) & (units) Table 22. Global Pegfilgrastim Injection Sales Volume Share by Type (2021-2026) Table 23. Global Pegfilgrastim Injection Sales Volume Share by Type (2027-2032) Table 24. Global Pegfilgrastim Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pegfilgrastim Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pegfilgrastim Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pegfilgrastim Injection Sales Value Share by Type (2021-2026) Table 28. Global Pegfilgrastim Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Neoplastic Diseases Table 30. Significant Companies of Blood Disorders Table 31. Significant Companies of Others Table 32. Global Pegfilgrastim Injection Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 33. Global Pegfilgrastim Injection Sales Volume by Application (2021-2026) & (units) Table 34. Global Pegfilgrastim Injection Sales Volume by Application (2027-2032) & (units) Table 35. Global Pegfilgrastim Injection Sales Volume Share by Application (2021-2026) Table 36. Global Pegfilgrastim Injection Sales Volume Share by Application (2027-2032) Table 37. Global Pegfilgrastim Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pegfilgrastim Injection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Pegfilgrastim Injection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Pegfilgrastim Injection Sales Value Share by Application (2021-2026) Table 41. Global Pegfilgrastim Injection Sales Value Share by Application (2027-2032) Table 42. Global Pegfilgrastim Injection Sales by Region: 2021 VS 2025 VS 2032 (units) Table 43. Global Pegfilgrastim Injection Sales by Region (2021-2026) & (units) Table 44. Global Pegfilgrastim Injection Sales Market Share by Region (2021-2026) Table 45. Global Pegfilgrastim Injection Sales by Region (2027-2032) & (units) Table 46. Global Pegfilgrastim Injection Sales Market Share by Region (2027-2032) Table 47. Global Pegfilgrastim Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Pegfilgrastim Injection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Pegfilgrastim Injection Sales Value Share by Region (2021-2026) Table 50. Global Pegfilgrastim Injection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Pegfilgrastim Injection Sales Value Share by Region (2027-2032) Table 52. Global Pegfilgrastim Injection Market Average Price (USD/unit) by Region (2021-2026) Table 53. Global Pegfilgrastim Injection Market Average Price (USD/unit) by Region (2027-2032) Table 54. Global Pegfilgrastim Injection Sales by Country: 2021 VS 2025 VS 2032 (units) Table 55. Global Pegfilgrastim Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Pegfilgrastim Injection Sales by Country (2021-2026) & (units) Table 57. Global Pegfilgrastim Injection Sales Market Share by Country (2021-2026) Table 58. Global Pegfilgrastim Injection Sales by Country (2027-2032) & (units) Table 59. Global Pegfilgrastim Injection Sales Market Share by Country (2027-2032) Table 60. Global Pegfilgrastim Injection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Pegfilgrastim Injection Sales Value Market Share by Country (2021-2026) Table 62. Global Pegfilgrastim Injection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Pegfilgrastim Injection Sales Value Market Share by Country (2027-2032) Table 64. CSPC Company Information Table 65. CSPC Business Overview Table 66. CSPC Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. CSPC Pegfilgrastim Injection Product Portfolio Table 68. CSPC Recent Development Table 69. Sandoz (Novartis) Company Information Table 70. Sandoz (Novartis) Business Overview Table 71. Sandoz (Novartis) Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Sandoz (Novartis) Pegfilgrastim Injection Product Portfolio Table 73. Sandoz (Novartis) Recent Development Table 74. Qilu Pharmaceutical Company Information Table 75. Qilu Pharmaceutical Business Overview Table 76. Qilu Pharmaceutical Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Qilu Pharmaceutical Pegfilgrastim Injection Product Portfolio Table 78. Qilu Pharmaceutical Recent Development Table 79. Mylan Company Information Table 80. Mylan Business Overview Table 81. Mylan Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Mylan Pegfilgrastim Injection Product Portfolio Table 83. Mylan Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Pfizer Pegfilgrastim Injection Product Portfolio Table 88. Pfizer Recent Development Table 89. Jiangsu Hengrui Medicine Company Information Table 90. Jiangsu Hengrui Medicine Business Overview Table 91. Jiangsu Hengrui Medicine Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Jiangsu Hengrui Medicine Pegfilgrastim Injection Product Portfolio Table 93. Jiangsu Hengrui Medicine Recent Development Table 94. Fresenius Kabi Company Information Table 95. Fresenius Kabi Business Overview Table 96. Fresenius Kabi Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Fresenius Kabi Pegfilgrastim Injection Product Portfolio Table 98. Fresenius Kabi Recent Development Table 99. Amgen Inc. Company Information Table 100. Amgen Inc. Business Overview Table 101. Amgen Inc. Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Amgen Inc. Pegfilgrastim Injection Product Portfolio Table 103. Amgen Inc. Recent Development Table 104. Coherus BioSciences, Inc. Company Information Table 105. Coherus BioSciences, Inc. Business Overview Table 106. Coherus BioSciences, Inc. Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Coherus BioSciences, Inc. Pegfilgrastim Injection Product Portfolio Table 108. Coherus BioSciences, Inc. Recent Development Table 109. Biocon Biologics Inc. Company Information Table 110. Biocon Biologics Inc. Business Overview Table 111. Biocon Biologics Inc. Pegfilgrastim Injection Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Biocon Biologics Inc. Pegfilgrastim Injection Product Portfolio Table 113. Biocon Biologics Inc. Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Pegfilgrastim Injection Distributors List Table 117. Pegfilgrastim Injection Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Pegfilgrastim Injection Product Image Figure 2. Global Pegfilgrastim Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pegfilgrastim Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pegfilgrastim Injection Sales (2021-2032) & (units) Figure 5. Global Pegfilgrastim Injection Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Pegfilgrastim Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Innovative Drugs Image Figure 10. Generic Drugs Image Figure 11. Global Pegfilgrastim Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Pegfilgrastim Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pegfilgrastim Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Pegfilgrastim Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pegfilgrastim Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pegfilgrastim Injection Sales Value Share by Type (2021-2032) Figure 17. Neoplastic Diseases Image Figure 18. Blood Disorders Image Figure 19. Others Image Figure 20. Global Pegfilgrastim Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 21. Global Pegfilgrastim Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Pegfilgrastim Injection Sales Volume Share by Application (2021-2032) Figure 23. Global Pegfilgrastim Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Pegfilgrastim Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Pegfilgrastim Injection Sales Value Share by Application (2021-2032) Figure 26. Global Pegfilgrastim Injection Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 27. Global Pegfilgrastim Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Pegfilgrastim Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Pegfilgrastim Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Pegfilgrastim Injection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Pegfilgrastim Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Pegfilgrastim Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Pegfilgrastim Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Pegfilgrastim Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Pegfilgrastim Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Pegfilgrastim Injection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Pegfilgrastim Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Pegfilgrastim Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Pegfilgrastim Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Pegfilgrastim Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Pegfilgrastim Injection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Pegfilgrastim Injection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Innovative Drugs
  • Generic Drugs
Applications
  • Neoplastic Diseases
  • Blood Disorders
  • Others
Companies covered
  • CSPC
  • Sandoz (Novartis)
  • Qilu Pharmaceutical
  • Mylan
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Amgen Inc.
  • Coherus BioSciences, Inc.
  • Biocon Biologics Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pegfilgrastim Injection Sales Value (2021-2032)
  4. 1.2.2 Global Pegfilgrastim Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Pegfilgrastim Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pegfilgrastim Injection Market Dynamics
  1. 2.1 Pegfilgrastim Injection Industry Trends
  2. 2.2 Pegfilgrastim Injection Industry Drivers
  3. 2.3 Pegfilgrastim Injection Industry Opportunities and Challenges
  4. 2.4 Pegfilgrastim Injection Industry Restraints
3 Pegfilgrastim Injection Market by Company
  1. 3.1 Global Pegfilgrastim Injection Company Revenue Ranking in 2025
  2. 3.2 Global Pegfilgrastim Injection Revenue by Company (2021-2026)
  3. 3.3 Global Pegfilgrastim Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Pegfilgrastim Injection Average Price by Company (2021-2026)
  5. 3.5 Global Pegfilgrastim Injection Company Ranking (2024-2026)
  6. 3.6 Global Pegfilgrastim Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Pegfilgrastim Injection Company Product Type and Application
  8. 3.8 Global Pegfilgrastim Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pegfilgrastim Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pegfilgrastim Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pegfilgrastim Injection Market by Type
  1. 4.1 Pegfilgrastim Injection Type Introduction
  2. 4.1.1 Innovative Drugs
  3. 4.1.2 Generic Drugs
  4. 4.2 Global Pegfilgrastim Injection Sales Volume by Type
  5. 4.2.1 Global Pegfilgrastim Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pegfilgrastim Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pegfilgrastim Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pegfilgrastim Injection Sales Value by Type
  9. 4.3.1 Global Pegfilgrastim Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pegfilgrastim Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pegfilgrastim Injection Sales Value Share by Type (2021-2032)
5 Pegfilgrastim Injection Market by Application
  1. 5.1 Pegfilgrastim Injection Application Introduction
  2. 5.1.1 Neoplastic Diseases
  3. 5.1.2 Blood Disorders
  4. 5.1.3 Others
  5. 5.2 Global Pegfilgrastim Injection Sales Volume by Application
  6. 5.2.1 Global Pegfilgrastim Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pegfilgrastim Injection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pegfilgrastim Injection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pegfilgrastim Injection Sales Value by Application
  10. 5.3.1 Global Pegfilgrastim Injection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pegfilgrastim Injection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pegfilgrastim Injection Sales Value Share by Application (2021-2032)
6 Pegfilgrastim Injection Regional Sales and Value Analysis
  1. 6.1 Global Pegfilgrastim Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pegfilgrastim Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Pegfilgrastim Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Pegfilgrastim Injection Sales by Region (2027-2032)
  5. 6.3 Global Pegfilgrastim Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pegfilgrastim Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pegfilgrastim Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pegfilgrastim Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Pegfilgrastim Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pegfilgrastim Injection Sales Value (2021-2032)
  12. 6.6.2 North America Pegfilgrastim Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pegfilgrastim Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Pegfilgrastim Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pegfilgrastim Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pegfilgrastim Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pegfilgrastim Injection Sales Value (2021-2032)
  21. 6.9.2 South America Pegfilgrastim Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pegfilgrastim Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pegfilgrastim Injection Sales Value Share by Country, 2025 VS 2032
7 Pegfilgrastim Injection Country-level Sales and Value Analysis
  1. 7.1 Global Pegfilgrastim Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pegfilgrastim Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pegfilgrastim Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Pegfilgrastim Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Pegfilgrastim Injection Sales by Country (2027-2032)
  6. 7.4 Global Pegfilgrastim Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pegfilgrastim Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pegfilgrastim Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pegfilgrastim Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pegfilgrastim Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pegfilgrastim Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSPC
  2. 8.1.1 CSPC Company Information
  3. 8.1.2 CSPC Business Overview
  4. 8.1.3 CSPC Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSPC Pegfilgrastim Injection Product Portfolio
  6. 8.1.5 CSPC Recent Developments
  7. 8.2 Sandoz (Novartis)
  8. 8.2.1 Sandoz (Novartis) Company Information
  9. 8.2.2 Sandoz (Novartis) Business Overview
  10. 8.2.3 Sandoz (Novartis) Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz (Novartis) Pegfilgrastim Injection Product Portfolio
  12. 8.2.5 Sandoz (Novartis) Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Pegfilgrastim Injection Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Pegfilgrastim Injection Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Pegfilgrastim Injection Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Jiangsu Hengrui Medicine
  32. 8.6.1 Jiangsu Hengrui Medicine Company Information
  33. 8.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 8.6.3 Jiangsu Hengrui Medicine Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Medicine Pegfilgrastim Injection Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Pegfilgrastim Injection Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 Amgen Inc.
  44. 8.8.1 Amgen Inc. Company Information
  45. 8.8.2 Amgen Inc. Business Overview
  46. 8.8.3 Amgen Inc. Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Inc. Pegfilgrastim Injection Product Portfolio
  48. 8.8.5 Amgen Inc. Recent Developments
  49. 8.9 Coherus BioSciences, Inc.
  50. 8.9.1 Coherus BioSciences, Inc. Company Information
  51. 8.9.2 Coherus BioSciences, Inc. Business Overview
  52. 8.9.3 Coherus BioSciences, Inc. Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Coherus BioSciences, Inc. Pegfilgrastim Injection Product Portfolio
  54. 8.9.5 Coherus BioSciences, Inc. Recent Developments
  55. 8.10 Biocon Biologics Inc.
  56. 8.10.1 Biocon Biologics Inc. Company Information
  57. 8.10.2 Biocon Biologics Inc. Business Overview
  58. 8.10.3 Biocon Biologics Inc. Pegfilgrastim Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biocon Biologics Inc. Pegfilgrastim Injection Product Portfolio
  60. 8.10.5 Biocon Biologics Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pegfilgrastim Injection Value Chain Analysis
  2. 9.1.1 Pegfilgrastim Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pegfilgrastim Injection Sales Mode & Process
  6. 9.2 Pegfilgrastim Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pegfilgrastim Injection Distributors
  9. 9.2.3 Pegfilgrastim Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst